Immunogenicity and safety of an intramuscular split-virion quadrivalent inactivated influenza vaccine in individuals aged ≥ 6 months in India

Immunogenicity and safety of an intramuscular split-virion quadrivalent inactivated influenza vaccine in individuals aged ≥ 6 months in India

A quadrivalent split-virion inactivated influenza vaccine (IIV4; Fluzone® Quadrivalent, Sanofi Pasteur) has been available in the US since 2013 for individuals aged ≥ 6 months. Here, we describe the results of an open-label, multicenter trial (WHO Universal Trial Number U1111-1143–8370) evaluating t...

Full description

Bibliographic Details
Main Authors: Sharad Agarkhedkar, Jugesh Chhatwal, Rajeev Zachariah Kompithra, Sanjay K. Lalwani, Arun Narayan, Vinay Muninarayanaswam, Nithya Gogtay, Kristin Dotter, Viviane Gresset-Bourgeois
Format: Article
Language:English
Published: Taylor & Francis Group 2019-04-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
quadrivalent inactivated influenza vaccine
safety
immunogenicity
children
adults
india
Online Access:http://dx.doi.org/10.1080/21645515.2019.1565259

Internet

http://dx.doi.org/10.1080/21645515.2019.1565259

Similar Items